Sunesis was a drug discovery company developing small-molecule therapeutics for the treatment of solid and haematologic tumours. The company went public in September 2005. Its clinical development programmes were ultimately unsuccessful and in 2021 it underwent a reverse merger with Viracta Therapeutics.